Instructor in Medicine, Dana-Farber Cancer Institute
Oncology
Dr. Peter S. Hammerman, MD
|
|
Give Review
Peter Hammerman is an expert in the field of Oncology. He researched medicine at Perelman School of Medicine at the University of Pennsylvania. Peter S. Hammerman is also published. He has 35 publications published. The lastest publication: "STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment.' He accepts Medicare.
Publications
- STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment.
- Therapeutic insights from genomic studies of head and neck squamous cell carcinomas.
- Genomic analysis of metastatic cutaneous squamous cell carcinoma.
- Integrative and comparative genomic analysis of HPV-positive and HPV-negative head and neck squamous cell carcinomas.
- EZH2 inhibition sensitizes BRG1 and EGFR mutant Lung tumours to TopoII inhibitors.
- Identification of Recurrent FGFR3-TACC3 Fusion Oncogenes from Lung Adenocarcinoma.
- Characterization of HPV and host genome interactions in primary head and neck Cancers.
- Kinase Domain Activation of FGFR2 Yields High-Grade Lung Adenocarcinoma Sensitive to a Pan-FGFR Inhibitor in a Mouse Model of NSCLC.
- Integrated RNA and DNA sequencing improves mutation detection in low purity Tumors.
- Ligand-associated ERBB2/3 activation confers acquired resistance to FGFR inhibition in FGFR3-dependent Cancer cells.
- Loss of Lkb1 and Pten Leads to Lung Squamous Cell Carcinoma with Elevated PD-L1 Expression.
- Acquired Resistance to Dasatinib in Lung Cancer Cell Lines Conferred by DDR2 Gatekeeper Mutation and NF1 Loss.
- Frequent mutation of receptor protein tyrosine phosphatases provides a mechanism for STAT3 hyperactivation in head and neck Cancer.
- Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors.
- Treatment-related toxicities in a phase II trial of dasatinib in patients with squamous cell carcinoma of the Lung.
- Oncogenic and drug-sensitive NTRK1 rearrangements in lung Cancer.
- Integrative radiogenomic profiling of squamous cell lung Cancer.
- Gene-expression data integration to squamous cell lung Cancer subtypes reveals drug sensitivity.
- Inhibitor-Sensitive FGFR2 and FGFR3 Mutations in Lung Squamous Cell Carcinoma.
- Mutational heterogeneity in Cancer and the search for new Cancer-associated genes.
- Frequent Mutation of the PI3K Pathway in Head and Neck Cancer Defines Predictive Biomarkers.
- Integrated cistromic and expression analysis of amplified NKX2-1 in Lung adenocarcinoma identifies LMO3 as a functional transcriptional target.
- Targeted therapy for squamous cell lung Cancer.
- Mapping the hallmarks of Lung adenocarcinoma with massively parallel sequencing.
- Inhibitor-sensitive FGFR1 amplification in human non-small cell lung Cancer.
- Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer.
- Multiple signaling pathways promote B lymphocyte stimulator dependent B-cell growth and survival.
- Pim and Akt oncogenes are independent regulators of hematopoietic cell growth and survival.
- The Pim kinases control rapamycin-resistant T cell survival and activation.
- Lymphocyte transformation by Pim-2 is dependent on nuclear factor-kappaB activation.
- Cytokine stimulation of aerobic glycolysis in hematopoietic cells exceeds proliferative demand.
- Akt-directed glucose metabolism can prevent Bax conformation change and promote growth factor-independent survival.
- The serine/threonine kinase Pim-2 is a transcriptionally regulated apoptotic inhibitor.
- Challenges in EGFRvIII detection in head and neck squamous cell carcinoma.
Schools
Perelman School of Medicine University of Pennsylvania
Massachusetts General Hospital
Procedures Preformed
- Thoracentesis
Conditions Treated
- Adrenal Gland Cancer
- Anemia
- ENT Cancer
- Laryngeal Cancer
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Education
-
Brigham and Women's Hospital -
Massachusetts General Hospital -
Perelman School of Medicine at the University of Pennsylvania
Hospital
-
Brigham and Women's Hospital -
Dana-Farber Cancer Institute
Drug Facts
| NPI NUMBER | 1518029545 | |
| NPPES Provider LastName | HAMMERMAN | |
| NPPES Provider FirstName | PETER | |
| NPPES Provider ZIPCode | 022155418 | |
| NPPES Provider State | MA | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 85.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1518029545 |
| Last Name Of The Provider | HAMMERMAN |
| First Name Of The Provider | PETER |
| View All |
Similar Doctors
|
|
Dr. Aparna Raj, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Bruce A. Chabner, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Marios Giannakis, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Alexi A. Wright, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Sadhna Vora, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Edwin Choy, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. David Barbie, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Lauren J. Oshry, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Omar Eton, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Boris Nicolai Bloch, MD
This Doctor is OpenDoctor Recommended.
|